Management of intermediate-grade lymphomas

ONCOLOGY

Volumn 12, Issue 10 SUPPL. 8, 1998, Pages 35-39

  Miller, Thomas P ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN SULFATE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; PREDNISONE; VINCRISTINE SULFATE;

CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; FOLLICULAR LYMPHOMA; HUMAN; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PROGNOSIS; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; LYMPHOMA, INTERMEDIATE-GRADE; PREDNISONE; PROGNOSIS; SALVAGE THERAPY; SURVIVAL RATE; VINCRISTINE;

EID: 0031731127     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. Cancer 49:84-93, 1982.
2. Grogan TM, Miller TP: Natural history and pre-treatment evaluation of non-Hodgkin's lymphomas, in Haskell CM (ed): Cancer Treatment, 4th ed, pp 979-1005. Philadelphia, WB Saunders Co, 1995.
3. Simon R, Durrleman S, Hoppe RT, et al: The non-Hodgkin's pathologic classification project: Long-term follow-up of 1153 patients with non-Hodgkin's lymphomas. Ann Intern Med 109:939-945, 1988.
4. Anderson T: Nodular mixed cell lymphoma: Is there a potential for prolonged disease free survival and cure?, in Bennett JM (ed). Controversies in the Management of Lymphomas, pp 225-238. Boston, Martinus Nijhoff, 1983.
5. Glick JH, Orlow EL: Nodular mixed lymphoma: Failure to demonstrate prolonged disease free survival and cure, in Bennet JM (ed), Controversies in the Management of Lymphomas, pp 239-256. Boston, Martinus Nijhoff, 1983.
6. Longo DL: What's the deal with follicular lymphomas? J Clin Oncol 11:202-208, 1993.
7. Metter GE, Nathwani B, Burke JS, et al: Morphologic subclassification of follicular lymphoma. Variability of diagnosis among hematopathologists: A collaborative study between the Repository Center and Pathology Panel for lymphoma clinical studies. J Clin Oncol 3:25-38, 1985.
8. Osborne CK, Norton L, Young RC: Nodular histiocytic lymphoma: An aggressive nodular lymphoma with potential for prolonged disease-free survival. Blood 56:98-103, 1980.
9. Kantarjian HM, McLaughlin P, Fuller LM: Follicular large cell lymphoma: Analysis and prognostic factors in 62 patients. J Clin Oncol 2:811-819, 1984.
10. Bartlett NL, Dorfman RF, Helpern J, et al: Follicular large cell lymphoma: Intermediate or low grade? J Clin Oncol 12:1349-1357, 1994.
11. Miller TP, LeBlanc M, Grogan TM, et al: Follicular lymphomas: Do histologic subtypes predict outcome?, in Miller TP, Grogan TM (eds): Hematology/Oncology Clinics of North America, vol 11, pp 893-900. Philadelphia, WB Saunders. 1997.
12. Anderson JR, Vose JM, Bierman PJ, et al: Clinical features and prognosis of follicular large-cell lymphoma: A report from the Nebraska Lymphoma Study Group. J Clin Oncol 11:218-224, 1993.
13. Nathwani BM, Kim H, Rappaport H: Malignant lymphoma, lymphoblastic. Cancer 38:964-983, 1976.
14. Fisher RI, Press OW, Miller TP, et al: Clinical course and therapy of mantle cell lymphoma, in: De Vita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology Updates IV, vol-10, pp 1-7. Philadelphia, JB Lippincott, 1996.
15. Fisher RI, Gaynor ER, Dahlberg S, et al: Phase III comparison of CHOP vs m-BACOD vs ProMACE-CytaBOM vs MACOP-B in patients with intermediate or high-grade non-Hodgkin's lymphoma: Results of SWOG-8516 (Intergroup 0067), the national high priority lymphoma study. N Engl J Med 328:1002-1006, 1993.
16. Chan JKC, Banks PM, Cleary ML, et al: A revised European-American classification of lymphoid neoplasms proposed by the International Lymphoma Study Group. Amer J Clin Path 103:543-560,1995.
17. Warnke R, Strauchen JA, Burke JS, et al: Morphologic types of diffuse large-cell lymphoma. Cancer 50:690-695, 1982.
18. Miller TP, Dahlberg S, Cassady JR, et al: Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate and high-grade non-Hodgkin's lymphoma. N Engl J Med 339: 21-26, 1998.
19. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995.
20. Martinelli M, Vignetti M, Zinzani PL, et al: High-dose chemotherapy followed by autologous bone marrow transplantation vs dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: A prospective randomized Italian multicenter study. J Clin Oncol 14:534-542, 1996.
21. Verdonck LF, van Putten WLJ, Hagenbeek A, et al: Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 332:1045-1051, 1995.
22. Haioun C, Lepage E, Grisselbrecht C, et al: Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: Updated results of the prospective study LNH87-2. J Clin Oncol 15:1131-1137, 1997.
23. Rodriguez-Monge EJ, Cabanillas F: Long-term follow-up of platinum-based salvage regimens: The M. D. Anderson Cancer Center Experience, in Miller TP, Grogan TM (eds): Hematology/Oncology Clinics of North America, vol 11, pp 937-947. Philadelphia, WB Saunders Co, 1997.
24. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aagressive non-Hodgkin's lymphoma. N Engl J Med 329:987-984, 1993.
25. Longo DL: ProMACE-MOPP vs ProMACE-CytaBOM: Updated results of the NCI randomized study, presentation at the Workshop on ProMACE-CytaBOM, Modena, Italy, September 22, 1997.
26. Gascoyne RD: Pathologic prognostic factors in diffuse aggressive non-Hodgkin's lymphoma, in Miller TP, Grogan TM (eds): Hematology/Oncology Clinics of North America, vol 11, pp 847-862. Philadelphia, WB Saunders, 1997.
27. Melnyk A, Rodriguez A, Pugh WC, et al: Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 89:4514-4520, 1997.
28. Vose JM, Peterson C, Bierman PJ, et al: Comparison of high-dose therapy and autologous bone marrow transplantation for T-cell and B-cell non-Hodgkin's lymphomas. Blood 76:424-431, 1990.
29. Klimecki WT, Futscher BW, Grogan TM, et al: P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 83:2451-2458, 1994.